HOSHINO Junichi
   Department   School of Medicine(Tokyo Women's Medical University Hospital), School of Medicine
   Position   Professor and Division head
Article types Original article
Language English
Peer review Non peer reviewed
Title がん薬物療法時の腎障害診療ガイドライン2022(第1章)　がん薬物療法対象患者の腎機能評価(Chapter 1: Evaluation of kidney function in patients undergoing anticancer drug therapy, from clinical practice guidelines for the management of kidney injury during anticancer drug therapy 2022)
Journal Formal name：International Journal of Clinical Oncology
Abbreviation：Int J Clin Oncol
ISSN code：13419625
Domestic / ForeginForegin
Publisher シュプリンガー・ジャパン(株)
Volume, Issue, Page 28(10),pp.1259-1297
Author and coauthor Muto Satoru, Matsubara Takeshi, Inoue Takamitsu, Kitamura Hiroshi, Yamamoto Kazuhiro, Ishii Taisuke, Yazawa Masahiko, Yamamoto Ryohei, Okada Naoto, Mori Kiyoshi, Yamada Hiroyuki, Kuwabara Takashige, Yonezawa Atsushi, Fujimaru Takuya, Kawano Haruna, Yokoi Hideki, Doi Kent, Hoshino Junichi, Yanagita Motoko
Publication date 2023/10/28
Summary The prevalence of CKD may be higher in patients with cancer than in those without due to the addition of cancer-specific risk factors to those already present for CKD. In this review, we describe the evaluation of kidney function in patients undergoing anticancer drug therapy. When anticancer drug therapy is administered, kidney function is evaluated to (1) set the dose of renally excretable drugs, (2) detect kidney disease associated with the cancer and its treatment, and (3) obtain baseline values for long-term monitoring. Owing to some requirements for use in clinical practice, a GFR estimation method such as the Cockcroft-Gault, MDRD, CKD-EPI, and the Japanese Society of Nephrology's GFR estimation formula has been developed that is simple, inexpensive, and provides rapid results. However, an important clinical question is whether they can be used as a method of GFR evaluation in patients with cancer. When designing a drug dosing regimen in consideration of kidney function, it is important to make a comprehensive judgment, recognizing that there are limitations regardless of which estimation formula is used or if GFR is directly measured. Although CTCAEs are commonly used as criteria for evaluating kidney disease-related adverse events that occur during anticancer drug therapy, a specialized approach using KDIGO criteria or other criteria is required when nephrologists intervene in treatment. Each drug is associated with the different disorders related to the kidney. And various risk factors for kidney disease associated with each anticancer drug therapy.
DOI 10.1007/s10147-023-02372-4
Document No. XA19140002<Pre 医中誌>
PMID 37382749